EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Datamonitor
Analyst
include the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companies
Articles
Computational Approach towards Designing Potent Inhibitors for Tuberculosis
Mycobacterium tuberculosis Mtbis one of the major infectious diseases posing a major threat to many developing countries including India It has been a daunting task for researchers and scientists to design and develop drugs that possess the potential to inhibit the disease in a specific manner without exhibiting side effects in humans Presently there are four drugs
Research Insights
Interpretable Machine Learning for High-dimensional Trajectories of Aging Health
We have built a computational model for individual aging trajectories of health and survival which contains physical functional and biological variables and is conditioned on demographic lifestyle and medical background information We combine techniques of modern machine learning with an interpretable interaction network where health
Case Studies
Heat Stable Hepatitis B vaccine
Partner Since Arecor has collaborated with PATH an international global health nonprofit organisation on the development of heat stable vaccines using the ArestatT technology Stabilisation of hepatitis B vaccine one of the many vaccines successfully st
Techno Trends
China's Regulatory Challenges Signal a Shift in Drug Approval Processes
Chinas evolving drug approval processes are impacting pharmaceutical companies and their strategies in the market
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Kinase Inhibitors as Antiviral Agents
Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.
Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.
Nanotechnology based Drug Delivery for Infectious Diseases
Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.
Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.
Untapped Opportunities in Southeast Asia
Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.
Architecting the Modern MICC for Life Sciences GCCs
Tanshuman Das is a life sciences technology and commercial leader with 17+ years of experience across pharmacovigilance, AI, CRO services and drug safety technology. He leads Sales & Marketing at Synapmed and focuses on translating AI and intelligent automation into practical, scalable solutions for life sciences organisations.
press releasesRead more...
First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
Clarity PharmaceuticalsASX CU Clarity or Company a clinicalstage radiopharmaceutical company with a mission to develop nextgeneration products that improve treatment outcomes for patients with cancer is pleased to announce that
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Pfizer Inc NYSE PFE and Blackstone Life Sciences Blackstone today announced a strategic cofunding agreement under which funds managed by Blackstone will pay up to a total of billion of development
Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease
Circio Holding ASA OSE CRNA a biotechnology company developing novel circular RNA expression technology for gene and cell therapy today announces a research collaboration with Solid Biosciences Inc
EirGenix and Merck enter Partnership to Strengthen Global Biologics Development Through Integrated BioReliance® Testing and Regulatory Support
EirGenix Inc and Merck have signed a nonlegally binding memorandum of understanding MOU to support EirGenixs IND and BLA enabling biologics pipeline development The MOU outlines Merck as one of EirGenixs preferred contract testing services vendors providing comprehensive BioReliance services
ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage
EventsRead more...
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWSRead more...
Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer
Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer
Eppendorf Invests €40 Million in New Manufacturing Facility in Penang, Malaysia
Eppendorf has started construction of a new manufacturing facility at Bandar Cassia Technology Park in Penang Malaysia
Lilly Invests US$3.5 Billion in New Manufacturing Facility for Obesity Medicines in Pennsylvania
Eli Lilly and Company has started construction of a US billion manufacturing facility in Lehigh Valley Pennsylvania as part of its plans to expand medicine production in the United States The new site is one of manufacturing facilities
Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer
Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC
Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol
Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...


